Kwaku Maxwell P, Burman Kenneth D
Endocrine Section, Washington Hospital Center, Washington, DC 20010-2975, USA.
J Intensive Care Med. 2007 Jul-Aug;22(4):224-31. doi: 10.1177/0885066607301361.
Untreated or unrecognized hypothyroidism may progress to severe decompensated hypothyroidism or myxedema coma. Relatively few cases are reported in the literature since the first case was apparently reported from the St. Thomas Hospital in London in 1879. The paucity of cases may be due to either underreporting or improvement in the diagnosis and treatment of uncomplicated hypothyroidism. However, despite the ready availability of sensitive thyrotropin assays, the recognition and treatment of myxedema coma remains a challenge. Although thyroid hormone treatment is highly effective when combined with ventilatory and hemodynamic support in the intensive care unit setting, controversies abound on the optimal and most effective choice of thyroid hormone preparation: thyroxine and triiodothyronine and in what amount. Accumulated evidence now shows that proper use of either thyroxine alone or in combination with triiodothyronine may be effective therapy.
未经治疗或未被识别的甲状腺功能减退症可能会进展为严重失代偿性甲状腺功能减退症或黏液性水肿昏迷。自1879年伦敦圣托马斯医院首次报告首例病例以来,文献中报道的病例相对较少。病例稀少可能是由于报告不足或单纯性甲状腺功能减退症的诊断和治疗有所改善。然而,尽管有灵敏的促甲状腺激素检测方法,但黏液性水肿昏迷的识别和治疗仍然是一项挑战。虽然在重症监护病房环境中,甲状腺激素治疗与通气和血流动力学支持相结合时非常有效,但关于甲状腺激素制剂(甲状腺素和三碘甲状腺原氨酸)的最佳和最有效选择以及用量存在诸多争议。目前积累的证据表明,单独使用甲状腺素或与三碘甲状腺原氨酸联合使用可能是有效的治疗方法。